Eric I. Richman

Eric Richman has more than 25 years of experience as a life science executive and venture investor and has been instrumental in the growth and success of a number of life science companies. As a member of the founding team of MedImmune, his responsibilities included the commercial launches of rare disease and oncology products, and he served in various roles in strategic planning, business development and international operations. In addition, he has worked at lifescience venture funds as a Venture Partner and Operating Partner. Eric has served as President & CEO of PharmAthene and Tyrogenex. He currently serves as a Director of several biotech companies including ADMA Biologics, Neubase Therapeutics, Zyversa, and others. He currently serves as Chairman of LabConnect, Inc. and former Board roles include PharmAthene, Inc., LEV Pharmaceuticals, Tyrogenex, Inc., Siga Technologies, and American Bank.

Eric earned his BA of Biomedical Science from the Sophie Davis School of Biomedical Education and MBA at the American Graduate School of International Management.